InMed has a lead drug candidate in clinical development—INM-755, a CBN-based topical dermatological cream for the treatment of epidermolysis bullosa; a second drug candidate in preclinical ...
Research into new bandaging aims to ease the agony experienced by those living with genetic skin condition Epidermolysis Bullosa (EB), commonly referred to as 'butterfly skin'. Scientists at ...
for the treatment of dystrophic epidermolysis bullosa (DEB) that was scheduled for December 6, 2024, and asked the Company to submit written responses to the remaining outstanding issues.
(Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona's resubmission of its Biologics License Application (BLA) for prademagene zamikeracel (pz ...